Bortezomib: Proteasome inhibition as a novel mechanism of cancer therapy-implications for hematological malignancies

Joesph Mikhael; Hong Chang

doi:10.2174/157018007779422541

Bortezomib: Proteasome inhibition as a novel mechanism of cancer therapy-implications for hematological malignancies

Joesph Mikhael, Hong Chang

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.

Original language	English (US)
Pages (from-to)	82-86
Number of pages	5
Journal	Letters in Drug Design and Discovery
Volume	4
Issue number	2
DOIs	https://doi.org/10.2174/157018007779422541
State	Published - Mar 2007

Keywords

Bortezomib
Cancer
Clinical trial
Multiple myeloma
Proteasome inhibitor

ASJC Scopus subject areas

Molecular Medicine
Pharmaceutical Science
Drug Discovery

Access to Document

10.2174/157018007779422541

Cite this

@article{da3a18faf2dc4953a30bc828c128e23f,

title = "Bortezomib: Proteasome inhibition as a novel mechanism of cancer therapy-implications for hematological malignancies",

abstract = "The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.",

keywords = "Bortezomib, Cancer, Clinical trial, Multiple myeloma, Proteasome inhibitor",

author = "Joesph Mikhael and Hong Chang",

year = "2007",

month = mar,

doi = "10.2174/157018007779422541",

language = "English (US)",

volume = "4",

pages = "82--86",

journal = "Letters in Drug Design and Discovery",

issn = "1570-1808",

publisher = "Bentham Science Publishers B.V.",

number = "2",

}

TY - JOUR

T1 - Bortezomib

T2 - Proteasome inhibition as a novel mechanism of cancer therapy-implications for hematological malignancies

AU - Mikhael, Joesph

AU - Chang, Hong

PY - 2007/3

Y1 - 2007/3

N2 - The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.

AB - The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.

KW - Bortezomib

KW - Cancer

KW - Clinical trial

KW - Multiple myeloma

KW - Proteasome inhibitor

UR - http://www.scopus.com/inward/record.url?scp=33846299169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846299169&partnerID=8YFLogxK

U2 - 10.2174/157018007779422541

DO - 10.2174/157018007779422541

M3 - Article

AN - SCOPUS:33846299169

SN - 1570-1808

VL - 4

SP - 82

EP - 86

JO - Letters in Drug Design and Discovery

JF - Letters in Drug Design and Discovery

IS - 2

ER -

Bortezomib: Proteasome inhibition as a novel mechanism of cancer therapy-implications for hematological malignancies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this